Cathie Wood's ARK Invest joins Cellares' $277M round to help bring cell therapies to more patients
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Cathie Wood's ARK Invest joins Cellares' $277M round to help bring cell therapies to more patients
ARK Invest has joined Cellares’ Series D with a $20M investment, bringing the total round to $277M. The syndicate includes BlackRock, Eclipse, T. Rowe Price, Baillie Gifford, Duquesne Family Office, Intuitive Ventures, Gates Frontier, EDBI, DC Global Ventures, DFJ Growth, and Willett Advisors. Funding will accelerate Cellares’ global Smart Factory network ahead of commercial-scale manufacturing in 2027. Cell therapy has long promised to trans…
Cathie Wood's ARK Invest Joins Cellares' $277 Million Series D
ARK joins an investor group that includes BlackRock, Eclipse, T. Rowe Price Investment Management, Inc., and Baillie Gifford, spanning public and private market institutional capital Investment comes as Cellares delivers its first GMP cell therapy doses to patients on the Cell Shuttle®, signs a 10-year commercial supply agreement with Cabaletta Bio, and advances its global more... The post Cathie Wood’s ARK Invest Joins Cellares’ $277 Million Se…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
